GYRE
NASDAQGyre Therapeutics Inc.
Price$5.69+0.12 (+2.06%)
02:15 PM07:45 PM
News · 26 weeks38-47%
2025-12-072026-05-31
Mix3290d
- SEC Filings15(47%)
- Insider12(38%)
- Other3(9%)
- Earnings2(6%)
Latest news
25 items- SECGyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- INSIDERChief Operating Officer Ye Weiguo exercised 7,500 shares at a strike of $0.75 and sold $45,680 worth of shares (7,500 units at $6.09) (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERChief Operating Officer Ye Weiguo exercised 22,220 shares at a strike of $0.75 and sold $136,653 worth of shares (22,220 units at $6.15) (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 4 filed by Director Zhang Ping4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERChief Operating Officer Ye Weiguo exercised 9,320 shares at a strike of $0.75 and sold $59,418 worth of shares (9,320 units at $6.38) (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERChief Operating Officer Ye Weiguo exercised 28,680 shares at a strike of $0.75 and sold $194,773 worth of shares (28,680 units at $6.79) (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SECGyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- SECGyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- PRGyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis TreatmentSAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for F351 (hydronidone) as a treatment for chronic hepatitis B (CHB)-induced liver fibrosis, which is liver damage resulting from the infection of the hepatitis B virus (HBV). The acceptance comes after the NMPA previously granted priority review status for F351 in March after Gyre submitted the NDA t
- SECSEC Form 10-Q filed by Gyre Therapeutics Inc.10-Q - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- INSIDERChief Executive Officer Luo Ying sold $82,927 worth of shares (10,315 units at $8.04) as part of a pre-agreed trading plan (SEC Form 4)4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Xiong Yue3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bergmann Joshua Benjamin3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wang Jialiang (Nmn)3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERNew insider Luo Ying claimed ownership of 2,575,541 shares (SEC Form 3)3 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SECGyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- PRGyre Therapeutics Reports First Quarter 2026 Results and Provides Business UpdateQ1 2026 revenue of $22.5 million; GAAP basic EPS: $(0.10) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-associated liver fibrosis submitted to China's CDE in March 2026 Completed acquisition of Cullgen in an approximately $300 million all-stock transaction, expanding pipeline into inflammatory diseases and cancers First patient enrolled in Phase 2/3 trial evaluating ETUARY™ for radiation-induced lung injury, including immune-related pneumonitis SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, the Company or Gyre Therapeutics) (NASDAQ:GYRE), an innovative, commercial stage biopharmaceutical company with
- INSIDERSEC Form 4 filed by Large owner Gni Group Ltd.4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Eastling Thomas Wilson4 - GYRE THERAPEUTICS, INC. (0001124105) (Issuer)
- SECSEC Form DEFA14A filed by Gyre Therapeutics Inc.DEFA14A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- SECGyre Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- PRGyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical CompanyPost-closing combined company has revenue-producing commercial asset and a robust pipeline of products and product candidates to address multiple therapeutic areas with a focus on fibrosis and inflammatory diseases.China innovation engine provides cost-efficient vehicle for discovery and early-stage development of targeted protein degraders and degrader-antibody conjugates. Strengthened leadership team in U.S., coupled with China operating presence to support future global growth. SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre", "Gyre Therapeutics" or the "Company") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing
- SECSEC Form DEFA14A filed by Gyre Therapeutics Inc.DEFA14A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- SECSEC Form DEF 14A filed by Gyre Therapeutics Inc.DEF 14A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
- SECAmendment: Gyre Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K/A - GYRE THERAPEUTICS, INC. (0001124105) (Filer)
GYRE FAQ
6 questionsWhere does GYRE stock trade?
Gyre Therapeutics Inc. (GYRE) is listed on NASDAQ.What sector and industry is GYRE in?
Gyre Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Gyre Therapeutics Inc. go public?
Gyre Therapeutics Inc. (GYRE) completed its IPO in 2006.What are analysts saying about GYRE?
Gyre Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $1600.00 price target on 2025-10-10. Recent price targets range from $1600.00 to $1800.00.What companies are similar to GYRE?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GYRE side-by-side with any of them on Quantisnow.How can I track GYRE on Quantisnow?
Quantisnow aggregates Gyre Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GYRE to receive live email and push alerts on every new disclosure.